On behalf of the laureates, I want to thank the Champalimaud Foundation; in particular, its President Leonor Beleza, who leads the foundation with such wisdom and grace, and the members of the Champalimaud Vision Award Jury. Of course, I also would like to acknowledge the vision and generosity of its founder, António Champalimaud. The Champalimaud Foundation challenges us to conquer the unknown, much like the Portuguese explorers who set sail from her shores. The Champalimaud Vision Award recognizes contributions in vision research, and in alternate years, it is given to groups delivering care in developing countries. However, the Foundation also supports an internal research program in neuroscience and cancer research, as well as a clinical cancer care in its Centre for the Unknown in Lisbon. It is well worth a visit.
I want to thank the other Champalimaud Laureates for allowing me to represent them. We all are honored by the award, and recognize that the group involved in translating the discovery of vascular endothelial growth factor (VEGF) to therapy is very much larger, and includes many other investigators, a few of whom I will mention. However, there also were many postdoctoral fellows, students, and clinicians, as well as industry scientists, and of course patients, whose important contributions I wish to acknowledge.
In the 1990s, the treatment of many retinal diseases was rather grim. For neovascular age-related macular degeneration (AMD), all we really had was a destructive laser treatment, which cauterized the vessels but also caused destruction of the neurosen-sory retina, leading to scotomas, or blind spots, and often decreased vision. This was not very rewarding, either for the patient or the treating clinician. Diabetic retinopathy was better controlled with laser photocoagulation, but even so, there were drawbacks and side effects. Treatment for retinal vein occlusion (RVO) also was of limited benefit.
Early in the 1990s, there was a confluence of researchers, especially in Boston, who were interested in ocular neovascularization (Fig. 1) . Together and separately, we investigated models of ocular neovascularization in human disease. We explored findings from tumor angiogenesis in ocular disease. Among these investigators, there was Dr Judah Folkman, who was, indeed, the ''Father of Angiogenesis''; and Harold Dvorak, who identified a soluble factor known as vascular permeability factor (VPF);
1 Napoleone Ferrara (Genentech), who isolated VEGF and recognized its role in angiogenesis; 2 The search for a secreted ''Factor X'' that stimulated ocular neovascularization dates back at least to 1948, when Michaelson postulated that a soluble and diffusible growth factor was responsible for retinal vascular growth in development and disease. 3 Clinicians recognized that damaged or ischemic retina secreted a factor that could leak out into other parts of the eye and cause new blood vessel growth, either in the retina, optic nerve, or on the iris (Fig. 2) . However, the exact identity of Factor X would remain elusive for several decades.
In the 1970s, Folkman's laboratory identified tumor angiogenesis factor, 4 and Folkman published his seminal theory of tumor angiogenesis in the November 1971 issue of New England Journal of Medicine: that angiogenesis, or the recruitment and growth of new blood vessels, was required for tumor growth. 5 However, Folkman's theory was met with skepticism.
In the 1980s, Pat D'Amore, Bert Glaser, Arnall Patz, and others looked for an angiogenic factor in the retina and vitreous. Fibroblast growth factors 1 and 2 (FGF-1 and FGF-2) were identified as angiogenic factors and potential candidates for Factor X. [6] [7] [8] [9] [10] Importantly, however, FGF did not meet all the criteria for Factor X; namely, it is not secreted. The identity of Factor X remained elusive.
In 1983, Harold Dvorak and Don Senger at Harvard Medical School isolated VPF from ascites fluid and tumor cells, and they demonstrated that it was a very potent permeability factor: 50,000 more potent than histamine. 1 In 1989, Napoleone Ferrara and others cloned, sequenced, and characterized VEGF, 2 which turned out to be the same molecule as VPF. 11 VEGF was a secreted endothelial cell mitogen and an angiogenesis factor that was regulated by hypoxia (a condition known to stimulate neovascularization in certain retinopathies). Ferrara identified high-affinity tyrosine kinase receptors for VEGF, 12 and demonstrated that heterozygous Vegf knockouts were embryonically lethal. 13 Intrigued by these findings, our groups set off in two directions to investigate the role of VEGF in ocular disease. First, Adamis et al.
14 grew retinal pigment epithelium (RPE) cells in culture and showed that they indeed produced VEGF (Fig. 3) , the first demonstration that ocular cells made this factor. They also demonstrated that this production was regulated by hypoxia (Fig. 4) . 15, 16 At the same time, we collected ocular fluid samples from a model of ischemic retinopathy in a nonhuman primate, in which experimental retinal ischemia following laser vein occlusion leads to iris neovascu- (Fig. 5 ). When we looked at VEGF/VPF levels with Dvorak, we saw that the protein was virtually nonexistent before neovascularization appeared, but rose very quickly to high levels that correlated closely with increasing severity of iris neovascularization, and levels decreased as the iris neovascularization regressed (Fig. 6) . 17 This was the first correlation of increased VEGF levels with ocular neovascularization in vivo. We also demonstrated that it was the ischemic retina that produced VEGF, specifically VEGF 121 and VEGF 165 (Fig. 7) , which are the secreted isoforms. 18 In collaboration with D'Amico and Folkman, Adamis and I collected vitreous samples from patients, and found that VEGF levels were significantly increased in eyes with proliferative diabetic retinopathy. 19 In a much larger study, 20 Lloyd Paul Aiello, working with George King and Napoleone Ferrara, collected samples from patients with diabetic retinopathy and RVO, and found that increased VEGF levels were associated with active neovascular disease (such as proliferative diabetic retinopathy and iris neovascularization), whereas VEGF levels were low in eyes with quiescent disease or in normal control eyes (Fig. 8) .
Aiello then went on, collaborating with Lois Smith and Eric Pierce, to inhibit VEGF using soluble VEGF receptors in a murine model of retinopathy of prematurity, and found that blocking VEGF in this fashion led to a pronounced reduction in retinal neovascularization, the first time that VEGF inhibition was shown to decrease neovascularization in the eye (Fig. 9) . 21 Adamis and I and our group, working with Ferrara, used the ischemic retinopathy and iris neovascularization model to test the A461 fulllength anti-VEGF antibody (essentially the precursor to Avastin), and we found that intravitreal injection of the antibody prevented any iris neovascularization, whereas a control antibody had no effect (Fig. 10) . 22 We also injected VEGF into normal eyes in our primate model, and found that this recapitulated all that we saw in neovascular eye disease, such as new blood vessels in the iris, neovascular glaucoma, retinal ischemia, and microangiopathy (Fig. 11) . 23, 24 At this point, in 1996, we were eager to develop a clinical treatment for patients. We had extensive evidence that VEGF had a key role in ischemic retinal disease in animal models and in humans. For neovascular AMD, there was perhaps less direct evidence for a causal role of VEGF, but there was definitely an unmet need, and Genentech (San Francisco, CA, USA) had a clear opportunity with several inhibitors of VEGF. Genentech, however, had many drugs in their pipeline at that time, and were perhaps influenced by Roche (Basel, Switzerland), who had supported clinical trials in AMD using a-interferon, which had negative outcomes. 25, 26 Genentech, thus, was less driven to pursue ophthalmic targets. Genentech continued to develop anti-VEGF drugs, primarily for cancer indications, but its ophthalmology program lagged somewhat. After several employees left to form Eyetech Pharmaceuticals (New York, NY) and develop pegaptanib (Macugen), the newly competitive environment led to renewed interest at Genentech for AMD therapies.
In the meantime, our group continued preclinical work with Ferrara et al. at Genentech, demonstrating that VEGF, indeed, was upregulated in the model of laser-induced choroidal neovascularization (CNV), which was relevant to AMD. Since we were unsure whether an intravitreally injected antibody could reach CNV, we tested whether intravenous delivery of anti-VEGF antibodies might be effective, and demonstrated that it could, indeed, reach the CNV (Fig. 12) and persist for several days. 27 As described by Ferrara, 28 the development of anti-VEGF agents continued, ultimately resulting in two molecules: bevacizumab (Avastin), the full-length antibody, and ranibizumab (Lucentis), the antibody fragment. Our group investigated intravitreal injection of the anti-VEGF antibody fragment (essentially Lucentis) in the laser-induced CNV model, and showed it could prevent neovascularization ( Fig.  13) , suggesting that this approach might be effective for neovascular AMD. 29 As I hinted earlier, the founding of Eyetech Pharmaceuticals led to some interesting outcomes. Its founders included former Genentech employees, Marty Glick and John McLaughlin, and three familiar ophthalmologists: David Guyer, Samir Patel, and Tony Adamis. They led the development of pegaptanib (Macugen) into clinical trials, and Phase 3 data showed its efficacy in slowing vision loss in all forms of neovascular AMD. 30 This was the first demonstration of efficacy of an antiangiogenic therapy in ophthalmology, and, thus, noteworthy. The vision outcomes with pegaptanib were not better than those achieved with verteporfin photodynamic therapy (Visudyne), a treatment developed earlier by our group, 31 but were applicable to a broader range of neovascular AMD subtypes.
On the other hand, the Phase 3 results using ranibizumab for neovascular AMD were dramatic (Fig. 14) . with the same dosing of ranibizumab as the MARINA trial.
The same year that the ranibizumab results were presented (in fact, at the same meeting), Philip Rosenfeld presented optical coherence tomography (OCT) data showing improvement in OCT findings with stable vision in a patient with neovascular AMD after intravitreal injection of bevacizumab (Fig. 15) . 34 This was dramatic and unexpected-we did not think that full-length antibody would be effective-but this stunning finding led to widespread off-label use of Avastin for neovascular AMD, which continues to this day.
Today, clinicians have multiple anti-VEGF agents to use: pegaptanib, bevacizumab (off label), ranibizumab, and aflibercept (Eylea; Table 1 ). With these drugs, more than 90% of patients avoid moderate vision loss, and approximately a third of patients achieve vision of 20/40 or better. More recently, the CATT, IVAN, and other trials have demonstrated similar vision outcomes with a variety of anti-VEGF agents. 35, 36 What about anti-VEGF therapy beyond AMD? The earliest evidence of efficacy in the eye was achieved in a model of ischemic retinopathy, essentially a model of RVO. 22 Therefore, it made sense to investigate anti-VEGF therapy for RVO. With the results of numerous Phase III studies of bevacizumab/ranibizumab and aflibercept, BRA-VO, 37 CRUISE, 38 COPERNICUS, 39, 40 GALI-LEO, 41 and VIBRANT, 42 we can conclude that anti-VEGF therapy is effective for RVO (Fig. 16) ; both branch retinal vein (BRVO) and central retinal vein (CRVO) occlusion.
Additionally, we had shown that VEGF injected 24 as well as endothelial cell hyperplasia. 43 Therefore, it is not surprising that anti-VEGF therapy also is successful for diabetic macular edema (DME), showing benefit in Phase III DRCRnet clinical trials, 44, 45 the RIDE/RISE trials, 46 and more recently in the Protocol T study comparing ranibizumab, aflibercept, and bevacizumab. 47 The story of VEGF, from discovery to therapy, shows that we not only solved for Factor X, but also that we were able to develop treatments that dramatically improved outcomes for patients for AMD, diabetic retinopathy, RVO, and other retinal disorders. Today, we recognize the contributions of the 2014 Champalimaud Vision Award Laureates and their respective teams, but also the contributions of many other physicians, scientists, funding agencies, industry partners, and especially the patients who enrolled in the clinical trials.
However, there is more to be done, and the research continues. We must improve our phenotyping and develop biomarkers for AMD, diabetic retinopathy, and RVO. We must develop treatments for early AMD. Moreover, I believe that we must target other pathways beyond VEGF, particularly in DME and RVO.
I would like to conclude with a quote from Leonor Beleza: ''Now we start afresh every day with the sense that today is already past and tomorrow is the present. We honour [Antonio Champalimaud's] philosophy of life: A search for excellence. . .outcomes. . .rigour. . .and knowledge.''
